Blockchain Registration Transaction Record

GeoVax Secures $2.5M Funding to Advance Cancer and Infectious Disease Therapies

GeoVax Labs raises $2.5M to advance COVID-19 vaccines for immunocompromised patients and cancer immunotherapies. Funding supports Phase 2 trials and novel treatments.

This funding directly impacts patients with limited treatment options, particularly immunocompromised individuals and cancer patients who may benefit from GeoVax's innovative approaches. The company's work addresses critical gaps in COVID-19 protection for vulnerable populations and advances novel cancer therapies that could offer new hope for those with advanced head and neck cancers. Additionally, the accelerated development path for their Mpox/smallpox vaccine could provide crucial protection against emerging infectious disease threats. For investors and the broader healthcare community, this represents progress toward potentially breakthrough treatments in areas where medical needs remain largely unmet.